CSIMarket
 
Acurx Pharmaceuticals inc   (ACXP)
Other Ticker:  
 
 
Price: $2.7200 $0.01 0.369%
Day's High: $2.92 Week Perf: -4.23 %
Day's Low: $ 2.70 30 Day Perf: -9.03 %
Volume (M): 121 52 Wk High: $ 8.82
Volume (M$): $ 329 52 Wk Avg: $3.02
Open: $2.79 52 Wk Low: $1.17



 Market Capitalization (Millions $) 34
 Shares Outstanding (Millions) 13
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Acurx Pharmaceuticals Inc
Acurx Pharmaceuticals Inc. is a pharmaceutical company that focuses on the development and commercialization of novel antibiotics for the treatment of bacterial infections. They have a particular emphasis on targeting gastrointestinal infections caused by Clostridioides difficile (C. difficile). The company's mission is to address the growing problem of antibiotic-resistant infections by developing innovative and effective therapies. They are committed to improving patient outcomes and providing healthcare professionals with new treatment options for difficult-to-treat infections.


   Company Address: 259 Liberty Ave. Staten Island 10305 NY
   Company Phone Number: 533-1469   Stock Exchange / Ticker: NASDAQ ACXP
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc Faces Stock Plunge and Financial Contraction in Fiscal Fourth Quarter of 2023

Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average.
The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.

Acurx Pharmaceuticals Inc

New Report Shows Acurx Pharmaceuticals Inc's Remarkable Share Growth Despite Operating Deficit



Acurx Pharmaceuticals Inc, a pharmaceutical company trading on the NASDAQ, has seen a notable increase in its shares in both the short and long term. The recent financial results for the third quarter of 2023 indicate an operating deficit. However, analysts and industry observers are optimistic about the company's performance based on the improvement relative to the same period in the previous year. This article examines the implications of these facts and ponders how they will affect Acurx Pharmaceuticals Inc in the future.
1. Share Gains and Increased Confidence:
Acurx Pharmaceuticals Inc experienced a 17.74% increase in shares over the past five trading days, and a 32.3% increase from the previous year. These gains demonstrate growing confidence in the company's future prospects, potentially attracting more investors and boosting market sentiment.

Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc Faces Operating Deficit in Q2 2023, Investors Remain Confident in Future Growth Potential


Introduction
Acurx Pharmaceuticals Inc (ACXP) has faced some challenges during the April to June 2023 reporting cycle, with revenue experiencing some moderation. However, despite these obstacles, shareholders remain optimistic and eagerly await new revenue sources to fuel the company's growth. This bullish outlook is backed by the belief that the current setbacks are temporary, and the company's potential for success in the future far outweighs its current performance.
Concerns over Operating Deficit
One of the key metrics that shareholders have been monitoring is the company's operating deficit, which stood at $-3.44524 million during the aforementioned period. This deficit, however, does not deter investors who understand that it takes time for revenue streams to materialize, especially in the pharmaceutical industry. Shareholders are confident that as the company develops and commercializes its pipeline of drugs, revenue will increase significantly, eradicating the current operating deficit.
Net Deficit Growth
While Acurx Pharmaceuticals Inc recorded a net deficit of $-3.445 million during the reporting cycle, up from $-2.621 million in the corresponding period a year ago, investors view this as an investment in future growth. These setbacks are part of the company's evolution and are expected during the early stages of the entity. Shareholders are confident that with a solid pipeline and an innovative approach, Acurx Pharmaceuticals will gradually overcome these deficits and establish a strong financial footing.

Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc. Faces Unexpected Operating Shortfall in Q1 2023

Financial analysts and shareholders at Acurx Pharmaceuticals Inc. were taken aback by some unexpected changes to the top-line of the company during the first quarter of 2023, which ended on March 31st. While their attention was drawn to the negative operating shortfall which stood at $-2.902957 million during this period, they were also eager to see new business models that could help the company grow and expand in the coming years.
Investors are less concerned about the current operational conduct of Acurx Pharmaceuticals, as most of them are waiting to see the company?s business plans and strategies to help sustain its growth and profitability in the long-term. Despite the strong reputation that the pharmaceutical company has built over the years, the market?s expectations have been continuously changing, leading to the need for more innovative approaches to running the company.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com